<!doctype html><html lang=tw><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>依洛尤單抗——極高危ASCVD患者的新希望 | 极客快訊</title><meta property="og:title" content="依洛尤單抗——極高危ASCVD患者的新希望 - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="tw"><meta property="og:image" content="https://p3.pstatp.com/large/pgc-image/153198987189420260f547c"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/f4f6ea93.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/f4f6ea93.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/f4f6ea93.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/f4f6ea93.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/f4f6ea93.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/f4f6ea93.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/f4f6ea93.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/f4f6ea93.html><meta property="article:published_time" content="2020-11-14T20:50:51+08:00"><meta property="article:modified_time" content="2020-11-14T20:50:51+08:00"><meta name=Keywords content><meta name=description content="依洛尤單抗——極高危ASCVD患者的新希望"><meta name=author content="极客快訊"><meta property="og:url" content="/tw/%E7%A7%91%E5%AD%B8/f4f6ea93.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快訊 Geek Bank</a></h1><p class=description>為你帶來最全的科技知識 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>依洛尤單抗——極高危ASCVD患者的新希望</h1></header><date class="post-meta meta-date">2020-11-14</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=tw/categories/%E7%A7%91%E5%AD%B8.html>科學</a></span></div><div class=post-content><img alt=依洛尤單抗——極高危ASCVD患者的新希望 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/153198987189420260f547c><p>◆</p><p>依洛尤單抗是國內<strong>唯一獲批</strong>的前蛋白轉化酶枯草溶菌素/Kexin 9型（PCSK9）抑制劑，屬於心血管慢病領域<strong>開創性的靶向降脂藥物</strong></p><p>◆</p><p>依洛尤單抗可以解決現有降脂藥物無法滿足的<strong>極高危</strong>動脈粥樣硬化性心血管疾病（<strong>ASCVD</strong>）患者的臨床需求，複合主要心血管事件風險降低15%<sup>2</sup></p><p>◆</p><p>依洛尤單抗可以為<strong>罕見病</strong><strong>純合子型家族性高膽固醇血癥</strong>（<strong>HoFH</strong>）患者提供有效治療方案</p><p>◆</p><p>依洛尤單抗是國家醫保目錄明確優先考慮的<strong>慢性病及罕見病用藥</strong></p><p>現有藥物治療下，極高危血脂異常患者LDL-C達標率僅為23.9%<sup>1</sup>，未滿足臨床需求巨大。依洛尤單抗在他汀基礎上進一步降低LDL-C水平平均達59%<sup>2</sup>，中國人群的LDL-C水平降幅更為顯著高達73.0%~78.9%，92.3-98.4%接受依洛尤單抗治療的患者達到指南推薦目標值（&lt;70 mg/dl）<sup>3</sup>。安全耐受性良好，每兩週注射一次140 mg或每月注射一次420 mg，使用簡便。</p><p><strong>中國獲批適應症：</strong></p><p>1. 心血管事件的預防: 在已有動脈粥樣硬化性心血管疾病的成人患者中，降低心肌梗死、卒中以及冠脈血運重建的風險。通過：與最大耐受劑量的他汀類藥物聯合用藥，伴隨或不伴隨其他降脂療法，或者在他汀類藥物不耐受或禁忌使用的患者中，單獨用藥或與其他降脂療法聯合用藥。</p><p>2. 用於成人或12歲以上青少年的純合子型家族性高膽固醇血癥。可與飲食療法和其他降低密度脂蛋白（LDL）治療（例如他汀類藥物、依折麥布、LDL分離術）合用，用於患有HoFH且需要進一步降低低密度脂蛋白膽固醇（LDL-C）的患者。</p><p>參考文獻：</p><p>1. Gitt AK, et al. Atherosclerosis (2016), doi: 10.1016/j.atherosclerosis.2016.09.004.</p><p>2. Sabatine MS, et al. N Engl J Med 2017;376:1713-22.</p><p>3. 依洛尤單抗注射液說明書</p><p>（來源：《國際循環》編輯部）</p><p>版</p><p>權</p><p>聲</p><p>明</p><p>版權屬《國際循環》所有。歡迎個人轉發分享。其他任何媒體、網站如需轉載或引用本網版權所有之內容須在醒目位置處註明“轉自《國際循環》”</p><p>我怎麼這麼好看</p></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>依洛</a></li><li><a>單抗</a></li><li><a>極高危</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list><li><a href=../../tw/%E7%A7%91%E6%8A%80/70e81242.html alt=恆瑞醫藥卡瑞利珠單抗、蘋果酸法米替尼膠囊聯合用藥獲批臨床 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p3.pstatp.com/large/pgc-image/f305ff5a20954e1aafd6e308054802a6 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/70e81242.html title=恆瑞醫藥卡瑞利珠單抗、蘋果酸法米替尼膠囊聯合用藥獲批臨床>恆瑞醫藥卡瑞利珠單抗、蘋果酸法米替尼膠囊聯合用藥獲批臨床</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/e2167e4.html alt=單抗電荷異質性知多少 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/4b01000194a123c7dc36 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/e2167e4.html title=單抗電荷異質性知多少>單抗電荷異質性知多少</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/a8620c8.html alt=國產貝伐珠單抗價格再降！恆瑞等將“參戰”羅氏安維汀面臨夾擊 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p3.pstatp.com/large/pgc-image/3fea1301974f40c184bf0c58b8f7f407 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/a8620c8.html title=國產貝伐珠單抗價格再降！恆瑞等將“參戰”羅氏安維汀面臨夾擊>國產貝伐珠單抗價格再降！恆瑞等將“參戰”羅氏安維汀面臨夾擊</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/b18d735.html alt=度伐利尤單抗注射液 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p3.pstatp.com/large/pgc-image/303735b09d464e4a87ca7afaf88033d3 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/b18d735.html title=度伐利尤單抗注射液>度伐利尤單抗注射液</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/e59f912.html alt=貝伐珠單抗一線治療老年mCRC安全 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/5e860004e1306b5457b7 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/e59f912.html title=貝伐珠單抗一線治療老年mCRC安全>貝伐珠單抗一線治療老年mCRC安全</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/ddd75de.html alt=貝伐珠單抗！百濟神州也殺進來了 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/60a52db658b6480e82e591fa79e89708 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/ddd75de.html title=貝伐珠單抗！百濟神州也殺進來了>貝伐珠單抗！百濟神州也殺進來了</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/a355e43.html alt=貝伐珠單抗在免疫和靶向治療時代治療非鱗非小細胞肺癌的挑戰 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p3.pstatp.com/large/pgc-image/5fed9c34f25641dabfb4f3acec815c28 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/a355e43.html title=貝伐珠單抗在免疫和靶向治療時代治療非鱗非小細胞肺癌的挑戰>貝伐珠單抗在免疫和靶向治療時代治療非鱗非小細胞肺癌的挑戰</a></li><hr></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>